These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21426474)

  • 21. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
    Lotan Y; Roehrborn CG
    J Urol; 2002 Jan; 167(1):75-9. PubMed ID: 11743279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?
    Bollmann M; Heller H; Bánkfalvi A; Griefingholt H; Bollmann R
    BJU Int; 2005 Jun; 95(9):1219-25. PubMed ID: 15892805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Contribution of fluorescence immunocytochemistry (uCyt+TM) in the postoperative surveillance of bladder cancer].
    Piaton E; Ruffion A; Collet F; Lopez JG; Champetier D; Hoch M; Perrin P; Devonec M
    Prog Urol; 2004 Jun; 14(3):315-9; discussion 319. PubMed ID: 15373172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
    van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
    Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences.
    Herr HW; Donat SM
    BJU Int; 2008 Nov; 102(9):1111-4. PubMed ID: 18778359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early results of bladder-cancer screening in a high-risk population of heavy smokers.
    Steiner H; Bergmeister M; Verdorfer I; Granig T; Mikuz G; Bartsch G; Stoehr B; Brunner A
    BJU Int; 2008 Aug; 102(3):291-6. PubMed ID: 18336612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
    Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
    Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer.
    Gudjónsson S; Isfoss BL; Hansson K; Domanski AM; Warenholt J; Soller W; Lundberg LM; Liedberg F; Grabe M; Månsson W
    Eur Urol; 2008 Aug; 54(2):402-8. PubMed ID: 18082934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is aneusomy of chromosome 9 alone a valid biomarker for urinary bladder cancer screening?
    Panani AD; Kozirakis D; Anastasiou J; Babanaraki A; Malovrouvas D; Roussos C
    Anticancer Res; 2006; 26(2A):1161-5. PubMed ID: 16619518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
    Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
    BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis.
    Nam RK; Redelmeier DA; Spiess PE; Sampson HA; Fradet Y; Jewett MA
    J Urol; 2000 Mar; 163(3):752-7. PubMed ID: 10687970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma.
    Gayed BA; Seideman C; Lotan Y
    J Urol; 2013 Oct; 190(4):1181-6. PubMed ID: 23583531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy.
    Whitson J; Berry A; Carroll P; Konety B
    BJU Int; 2009 Aug; 104(3):336-9. PubMed ID: 19220253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicolor fluorescence in situ hybridization assay: A monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: A prospective study.
    Galván AB; Salido M; Espinet B; Placer J; Pijuan L; Juanpere N; Lloreta J; Solé F; Gelabert-Mas A
    Cancer Cytopathol; 2011 Dec; 119(6):395-403. PubMed ID: 21717592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives.
    Yossepowitch O; Herr HW; Donat SM
    J Urol; 2007 Apr; 177(4):1277-82; discussion 1282. PubMed ID: 17382711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology.
    Ray ER; Chatterton K; Khan MS; Thomas K; Chandra A; O'Brien TS
    BJU Int; 2009 May; 103(10):1363-7. PubMed ID: 19076151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
    Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
    J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
    Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
    Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.